Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 1
2013 2
2014 3
2015 4
2016 8
2017 2
2018 2
2019 6
2020 2
2021 8
2022 6
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, Sakaguchi S, Nokihara H, Kanai K, Tsunemi T, Hattori N, Hatanaka Y, Sonoo M, Atsuta N, Sobue G, Shimizu T, Shibuya K, Ikeda K, Kano O, Nishinaka K, Kojima Y, Oda M, Komai K, Kikuchi H, Kohara N, Urushitani M, Nakayama Y, Ito H, Nagai M, Nishiyama K, Kuzume D, Shimohama S, Shimohata T, Abe K, Ishihara T, Onodera O, Isose S, Araki N, Morita M, Noda K, Toda T, Maruyama H, Furuya H, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. Oki R, et al. JAMA Neurol. 2022 Jun 1;79(6):575-583. doi: 10.1001/jamaneurol.2022.0901. JAMA Neurol. 2022. PMID: 35532908 Free PMC article. Clinical Trial.
Regret-sensitive treatment decisions.
Fujii Y, Osaki Y. Fujii Y, et al. Among authors: osaki y. Health Econ Rev. 2018 Aug 6;8(1):14. doi: 10.1186/s13561-018-0198-2. Health Econ Rev. 2018. PMID: 30083822 Free PMC article.
Segmental Zoster Paresis Accompanied by Horner's Syndrome.
Hanada K, Osaki Y, Fujita K, Fukumoto T, Fukushima K, Kito H, Izumi Y. Hanada K, et al. Among authors: osaki y. Intern Med. 2023;62(18):2743-2746. doi: 10.2169/internalmedicine.0578-22. Epub 2023 Sep 15. Intern Med. 2023. PMID: 37722924 Free PMC article.
An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study.
Haji S, Fujita K, Oki R, Osaki Y, Miyamoto R, Morino H, Nagano S, Atsuta N, Kanazawa Y, Matsumoto Y, Arisawa A, Kawai H, Sato Y, Sakaguchi S, Yagi K, Hamatani T, Kagimura T, Yanagawa H, Mochizuki H, Doyu M, Sobue G, Harada M, Izumi Y. Haji S, et al. Among authors: osaki y. JMIR Res Protoc. 2023 Jan 30;12:e42032. doi: 10.2196/42032. JMIR Res Protoc. 2023. PMID: 36716091 Free PMC article.
A novel COL4A1 variant associated with recurrent epistaxis and glioblastoma.
Muto K, Miyamoto R, Terasawa Y, Shimatani Y, Hara K, Kakimoto T, Fukumoto T, Osaki Y, Fujita K, Harada M, Uehara H, Takagi Y, Izumi Y. Muto K, et al. Among authors: osaki y. Hum Genome Var. 2021 May 14;8(1):18. doi: 10.1038/s41439-021-00150-0. Hum Genome Var. 2021. PMID: 33990551 Free PMC article.
Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.
Ikeuchi N, Igata F, Kinoshita E, Kawabata T, Tan I, Osaki Y, Otsuka R, On R, Ikeda T, Nakao A, Sasaki T, Aoyama T, Hirano R, Harada T, Ebi N, Fujita M, Inoue H. Ikeuchi N, et al. Among authors: osaki y. Anticancer Res. 2023 Feb;43(2):713-724. doi: 10.21873/anticanres.16210. Anticancer Res. 2023. PMID: 36697078
49 results